---
document_datetime: 2026-01-28 16:02:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/biktarvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: biktarvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6708105
conversion_datetime: 2026-01-29 12:42:23.425312
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Biktarvy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000274445 | In view of available data on tenofovir | 16/10/2025                          | 12/12/2025                                  | SmPC and PL                      | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | alafenamide excretion in breastmilk from the literature, the PRAC concluded that the product information of products containing tenofovir alafenamide should be amended accordingly. In view of available data on bictegravir / emtricitabine / tenofovir alafenamide and weight increase from the literature and clinical trial data, the PRAC considers a causal relationship between bictegravir / emtricitabine / tenofovir alafenamide and weight increase at least a reasonable possibility. The PRAC concluded that the product information of bictegravir / emtricitabine / tenofovir alafenamide should be amended accordingly. In view of available data on Biktarvy and the interaction with zinc based on in vitro data and post marketing data, the PRAC considers that zinc is a possible chelator of bictegravir / emtricitabine / tenofovir alafenamide. The PRAC concluded that the product information of bictegravir / emtricitabine / tenofovir   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000284417 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 02/09/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000244876 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (IB) - To provide a new RMP version to update the due date for the final CSR submission for study GS-US-380-1474 from \"Anticipated submission by Q1 2025\" to \"Anticipated submission by Q1 2026\".      | 25/02/2025 | N/A |